Comprehensive updates offer evidence-based strategies for managing migraines in Canadian patients
The Canadian Headache Society (CHS) has released its updated Migraine Prevention Guidelines, incorporating a comprehensive systematic review and meta-analysis.
This update replaces the 2012 guidelines and addresses advancements in therapies and the need for chronic migraine prevention recommendations.
The guidelines promise to assist healthcare professionals in delivering evidence-based treatment to improve outcomes for Canadians living with migraines.
The systematic review evaluated 61 studies, providing insights into 16 therapies. Among these, anti-calcitonin gene-related peptide (CGRP) agents approved by Health Canada between 2018 and 2024 emerged as significant options for episodic and chronic migraine prevention.
Other treatments, such as propranolol, topiramate, and onabotulinumtoxinA, were also highlighted for their efficacy in managing chronic migraine.
The review downgraded topiramate for episodic migraine to a weak recommendation, citing concerns over efficacy and tolerability.
Gabapentin also received a weak recommendation against its use for episodic migraine. In contrast, new therapies, including memantine, levetiracetam, enalapril, and melatonin, were weakly recommended for episodic migraine.
The guidelines were prepared by a multidisciplinary team of experts, including neurologists and information specialists.
Suzanne Christie, CHS President, emphasised the guidelines' purpose, saying, “Our goal is to improve the quality of care for individuals living with migraine by providing healthcare professionals with the tools and knowledge they need to effectively manage this complex condition.”
The updated Migraine Prevention Guidelines are accessible on the Canadian Headache Society's website. Healthcare professionals are encouraged to review these recommendations to stay informed about the latest preventive treatment strategies.
